I'm LongbridgeAI, I can summarize articles.Frontage (1521.HK) soared nearly 49% in Hong Kong trading to a 52-week high, last at HK$2.22.
The life sciences tools and services industry index rose 4.4% over the same period.
The stock resumed trading after a consortium led by Tigermed and named SanRex proposed a privatization offer at HK$2.37 per share, representing a premium of about 59.1%. Upon completion, the company will be delisted via a scheme of arrangement, with shareholders receiving a cancellation price plus a contingent payment based on proceeds.
Frontage will also be split as part of the transaction. Its bioanalysis and DMPK businesses will be sold to Charles River Laboratories (CRL), overseas non-target businesses will be acquired by Chairman Li Song, and domestic non-target businesses will be retained by Tigermed.
Based on public media reports. AI-generated; not investment advice.
